H3 Biomedicine has named Markus Warmuth, M.D., president and chief executive officer, effective immediately.

Warmuth joined the H3 Biomedicine team in August 2011 as chief scientific officer. Most recently, he had served as head of oncology drug discovery for the Novartis Institute for Biomedical Research (NIBR). In his role at NIBR, he directed broad aspects of the company's global oncology drug discovery portfolio from target discovery to clinical development.

"Markus provides the scientific vision of human cancer genetics revealing cancer dependencies and targeting those dependencies, even when they are viewed as challenging, by exploiting advances in modern asymmetric synthesis and chemical biology. He also brings industrial experience in leadership, management and cancer drug development. He is a perfect fit for the intensive, fast-paced environment of H3, where we want to bring hope and health urgently to patients living with cancer," said Stuart L. Schreiber, Ph.D., H3 scientific founder and founding director of Chemical Biology at the Broad Institute of Harvard and MIT.